Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Corcept Therapeutics's Debt-to-Equity or its related term are showing as below:
HAM:HTD'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.01 Max: 0.72
Current: 0.02
During the past 13 years, the highest Debt-to-Equity Ratio of Corcept Therapeutics was 0.72. The lowest was 0.00. And the median was 0.01.
HAM:HTD's Debt-to-Equity is ranked better than 88.19% of 965
companies
in the Biotechnology industry
Industry Median: 0.16
vs HAM:HTD: 0.02
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Corcept Therapeutics Debt-to-Equity Related Terms
Corcept Therapeutics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Corcept Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:HTD vs PRAX, IBRX, NUVL: Debt-to-Equity Comparison
For the Biotechnology subindustry, Corcept Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corcept Therapeutics Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corcept Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Corcept Therapeutics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corcept Therapeutics (HAM:HTD) has a Debt-to-Equity of 0.02 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Corcept Therapeutics and its competitors. This is 100% above median its historical median of 0.01. According to the industry distribution chart, Corcept Therapeutics ranks #114 out of 965 companies in the Biotechnology industry, placing it in the top 11.8%.
Is Corcept Therapeutics' Debt-to-Equity too high?
Corcept Therapeutics' current Debt-to-Equity of 0.02 is 100% above median its 10-year median of 0.01. The Biotechnology industry median Debt-to-Equity is 0.16. Corcept Therapeutics' value of 0.02 is 87.5% below this industry median. Based on the distribution chart, Corcept Therapeutics ranks #114 out of 965 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Corcept Therapeutics has a GF Score™ of 88/100, reflecting its overall financial health beyond just this single metric.
How does Corcept Therapeutics' Debt-to-Equity compare to PRAX and IBRX?
According to the Biotechnology industry distribution chart, Corcept Therapeutics ranks #114 out of 965 companies for Debt-to-Equity. This places Corcept Therapeutics in the top 12% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.16. Corcept Therapeutics' value of 0.02 is 87.5% below this benchmark. While the company's 10-year median is 0.01 vs. the industry median of 0.16, Corcept Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Corcept Therapeutics's current Debt-to-Equity of 0.02 is 87.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Corcept Therapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corcept Therapeutics's current Debt-to-Equity is 0.02, which is 100% above median its own 10-year median of 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corcept Therapeutics stock overvalued right now?
Corcept Therapeutics (HAM:HTD) has a current Debt-to-Equity of 0.02. The stock's GF Value™ is €55.38, compared to a current price of €78.18 — trading 41.2% above its estimated fair value. The current Debt-to-Equity is 0.02, which is 100% above median its 10-year median of 0.01 and 87.5% below the Biotechnology industry median of 0.16. Corcept Therapeutics' overall GF Score™ is 88/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Corcept Therapeutics (HAM:HTD), the current Debt-to-Equity is 0.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Corcept Therapeutics (HAM:HTD) Overvalued in 2026?
Based on GuruFocus' analysis, Corcept Therapeutics stock appears to be overvalued.
The current stock price of €78.18 is trading 41.2% above its estimated GF Value™ of €55.38.
Key valuation signals for HAM:HTD:
Debt-to-Equity: 0.02 (100% above median its 10-year median of 0.01)
GF Value™: €55.38 vs. price of €78.18 (41.2% above fair value)
Industry Position: 87.5% below the Biotechnology median (#114 of 965)
No single metric tells the full story. See the HAM:HTD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
88GF Score
Get the complete analysis for HAM:HTD
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:HTD has been successfully added to your 
